ABBV vs PFE
By Alex · Tickerpine
AbbVie Inc. vs Pfizer Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | PFE |
|---|---|---|
| Price | $253.35 | $24.29 |
| Market cap | $447.62B | $138.44B |
| P/E ratio | 123.6 | 18.5 |
| ROE | — | 8.31% |
| Profit margin | 5.79% | 11.83% |
| Revenue growth | 12.40% | 5.40% |
| Dividend yield | 2.73% | 7.08% |
| Beta | 0.31 | 0.29 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs PFE in plain English
- ABBV is the bigger company — about 3.2× the market cap of PFE.
- PFE is cheaper on earnings (P/E 18.5 vs 123.6).
- ABBV is growing revenue faster (12% vs 5%).
- PFE has the higher dividend yield (7.08% vs 2.73%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
PFE return calculator
See what $1,000 in Pfizer Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.